Ana Gupte, Leerink Partners, and Leonard Yaffe, StocDoc Partners, discuss stocks poised to win amid Trump's healthcare reform.
Jim Cramer gives his opinion on various stocks from callers at lightning speed.
Jim Cramer found the unexpected stocks behind the rally, pushing the market to all-time highs.
Pharmaceutical companies don't expect President-elect Donald Trump to continue the tough rhetoric on drug prices.
One anti-anxiety drug, Ativan, had an average unit cost increase of a stunning 1,264 percent between 2014 and 2015 for Medicaid.
Les Funtleyder, ESquare portfolio manager, shares his take on the healthcare sector amid a Trump presidency.
Jim Cramer gives his opinion in the Lightning Round, including one retailer that could gain strength out of the election.
Pharmaceutical stocks have been under pressure, but certain companies are doing things right, former Medtronic CEO Bill George says.
Some of the names on the move ahead of the open.
These are the stocks posting the largest moves after the bell on Tuesday, including: Square, Gilead Sciences, Herbalife and more.
CNBC's Meg Tirrell reports on Gilead's earnings conference call, including what CEO John Milligan has to say.
Earnings are out for Gilead. CNBC's Meg Tirrell reports the details. “Fast Money” trader Jon Najarian weighs in.
U.S. stock index futures pointed to a flat to slightly higher open, as investors prepared for further earnings and more election news.
Jim Cramer rattles off his take on caller favorite stocks, including this healthcare stock standing alone in a tough cohort.
CNBC's Meg Tirrell reports details from Amgen's earnings conference call, including what CEO Robert Bradway has to say. The "Fast Money" traders weigh in on the biotech sector.
Jefferies shares its favorite biotech stock ideas to pick up amid the recent share price weakness due to Hillary Clinton's rising poll numbers.
These five names are the cheapest stocks in the market right now. Are they worthy buys at these levels?
Leigh Drogen, Estimize CEO and co-founder, shares his list of Q3 potential earnings beats and misses.
Jim Cramer explained the silver lining of the market going into earnings season.
Jim Cramer says uncertainty surrounding a Democratic win for the White House puts drug stocks in the danger zone.